Retatrutide 32mg LY3437943
Retatrutide is an investigational triple-receptor agonist targeting GIP, GLP-1 and glucagon pathways. It is being researched for its potential effects on body weight, appetite regulation, glucose metabolism and metabolic health. Research areas include: weight...
Retatrutide is an investigational triple-receptor agonist targeting GIP, GLP-1 and glucagon pathways. It is being researched for its potential effects on body weight, appetite regulation, glucose metabolism and metabolic health.
Research areas include: weight management, appetite regulation, glucose control, metabolic health, type 2 diabetes and obesity-related conditions.
Important: Retatrutide is an investigational compound and is not approved for general human use. This product is provided for research purposes only and is not intended to diagnose, treat, cure or prevent any disease or medical condition.
| Form | Lyophilised powder |
| Purity (HPLC) | 99%+ |
| Appearance | White lyophilised solid |
| Solubility | Bacteriostatic / sterile water |
| Storage | Lyophilised at -20°C, reconstituted at 2 to 8°C |
The Certificate of Analysis for lot GX-2026 confirms an HPLC purity of 99%+ and identity confirmed by mass spectrometry.
View in COA libraryThe Safety Data Sheet describes handling, storage and disposal information for this research compound. Always follow standard laboratory safety practice.
View in SDS libraryJoin the research list.
New compounds, batch releases and COA drops, sent before they hit the catalogue.